SU1470186A3 - Способ получени гетероциклических соединений - Google Patents
Способ получени гетероциклических соединений Download PDFInfo
- Publication number
- SU1470186A3 SU1470186A3 SU853979033A SU3979033A SU1470186A3 SU 1470186 A3 SU1470186 A3 SU 1470186A3 SU 853979033 A SU853979033 A SU 853979033A SU 3979033 A SU3979033 A SU 3979033A SU 1470186 A3 SU1470186 A3 SU 1470186A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- group
- hydroxy
- thio
- formula
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 44
- 238000000034 method Methods 0.000 title claims description 6
- -1 amino, carboxy Chemical group 0.000 claims abstract description 21
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 5
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims abstract 3
- 229910052736 halogen Inorganic materials 0.000 claims abstract 3
- 125000002252 acyl group Chemical group 0.000 claims abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 239000001301 oxygen Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical group C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000002391 heterocyclic compounds Chemical class 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 150000003852 triazoles Chemical class 0.000 claims 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 abstract description 4
- 208000014644 Brain disease Diseases 0.000 abstract description 2
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 208000026935 allergic disease Diseases 0.000 abstract description 2
- 239000005557 antagonist Substances 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 230000000302 ischemic effect Effects 0.000 abstract description 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 229910052783 alkali metal Inorganic materials 0.000 abstract 1
- 150000001340 alkali metals Chemical class 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 abstract 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract 1
- 150000002366 halogen compounds Chemical class 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 241000700198 Cavia Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002052 anaphylactic effect Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 210000003405 ileum Anatomy 0.000 description 3
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- 229940070710 valerate Drugs 0.000 description 3
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Natural products CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000009989 contractile response Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- PWWSSIYVTQUJQQ-UHFFFAOYSA-N distearyl thiodipropionate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCSCCC(=O)OCCCCCCCCCCCCCCCCCC PWWSSIYVTQUJQQ-UHFFFAOYSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- ZLBRYWTYPCYOKF-UHFFFAOYSA-N 2-hydroxy-1-phenylpentan-1-one Chemical group CCCC(O)C(=O)C1=CC=CC=C1 ZLBRYWTYPCYOKF-UHFFFAOYSA-N 0.000 description 1
- BFPGHQLMXCDMGY-UHFFFAOYSA-N 4-hydroxy-1-phenylpentan-1-one Chemical compound CC(O)CCC(=O)C1=CC=CC=C1 BFPGHQLMXCDMGY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 231100000668 minimum lethal dose Toxicity 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- KOODSCBKXPPKHE-UHFFFAOYSA-N propanethioic s-acid Chemical compound CCC(S)=O KOODSCBKXPPKHE-UHFFFAOYSA-N 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- XKGLSKVNOSHTAD-UHFFFAOYSA-N valerophenone Chemical compound CCCCC(=O)C1=CC=CC=C1 XKGLSKVNOSHTAD-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP23899184 | 1984-11-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1470186A3 true SU1470186A3 (ru) | 1989-03-30 |
Family
ID=17038289
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU853979033A SU1470186A3 (ru) | 1984-11-12 | 1985-11-11 | Способ получени гетероциклических соединений |
| SU864028334A SU1438610A3 (ru) | 1984-11-12 | 1986-10-21 | Способ получени гетероциклических соединений |
| SU864028350A SU1493105A3 (ru) | 1984-11-12 | 1986-10-27 | Способ получени гетероциклических соединений |
| SU864028381A SU1452481A3 (ru) | 1984-11-12 | 1986-10-27 | Способ получени гетероциклических соединений |
| SU864028405A SU1454249A3 (ru) | 1984-11-12 | 1986-10-29 | Способ получени гетероциклических соединений или их фармацевтически приемлемых солей щелочного металла |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU864028334A SU1438610A3 (ru) | 1984-11-12 | 1986-10-21 | Способ получени гетероциклических соединений |
| SU864028350A SU1493105A3 (ru) | 1984-11-12 | 1986-10-27 | Способ получени гетероциклических соединений |
| SU864028381A SU1452481A3 (ru) | 1984-11-12 | 1986-10-27 | Способ получени гетероциклических соединений |
| SU864028405A SU1454249A3 (ru) | 1984-11-12 | 1986-10-29 | Способ получени гетероциклических соединений или их фармацевтически приемлемых солей щелочного металла |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JPS62174057A (enExample) |
| SU (5) | SU1470186A3 (enExample) |
| ZA (1) | ZA858493B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61186368A (ja) * | 1985-02-14 | 1986-08-20 | Kyorin Pharmaceut Co Ltd | 新規な抗アレルギ−薬およびその製造方法 |
| US5453433A (en) * | 1994-05-13 | 1995-09-26 | Sterling Winthrop Inc. | Thiadiazoles and antipicornaviral compositions |
| RU2144534C1 (ru) * | 1997-06-30 | 2000-01-20 | Николай Иванович Трубчанин | Способ получения морфолиния 3-метил-1,2,4-триазолил-5-тиоацетата, проявляющего гепатозащитную, ранозаживляющую и противовирусную активность |
| WO1999004815A1 (fr) * | 1997-07-24 | 1999-02-04 | Yamanouchi Pharmaceutical Co., Ltd. | Compositions medicinales hypocholesterolemiantes |
| EP1471063A1 (en) * | 2003-02-28 | 2004-10-27 | Exonhit Therapeutics S.A. | Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis |
-
1985
- 1985-11-05 ZA ZA858493A patent/ZA858493B/xx unknown
- 1985-11-11 SU SU853979033A patent/SU1470186A3/ru active
- 1985-11-12 JP JP60253562A patent/JPS62174057A/ja active Granted
-
1986
- 1986-10-21 SU SU864028334A patent/SU1438610A3/ru active
- 1986-10-27 SU SU864028350A patent/SU1493105A3/ru active
- 1986-10-27 SU SU864028381A patent/SU1452481A3/ru active
- 1986-10-29 SU SU864028405A patent/SU1454249A3/ru active
Also Published As
| Publication number | Publication date |
|---|---|
| JPS62174057A (ja) | 1987-07-30 |
| JPS6335626B2 (enExample) | 1988-07-15 |
| SU1454249A3 (ru) | 1989-01-23 |
| SU1438610A3 (ru) | 1988-11-15 |
| ZA858493B (en) | 1986-07-30 |
| SU1452481A3 (ru) | 1989-01-15 |
| SU1493105A3 (ru) | 1989-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0219436B1 (en) | Thiazole derivative and leukotriene antagonist containing the same as the effective ingredients | |
| RU2114108C1 (ru) | ПРОИЗВОДНЫЕ 7-(2-АМИНОЭТИЛ)БЕНЗОТИАЗОЛОНА ИЛИ ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, ПРОИЗВОДНЫЕ N-[2-(4-ГИДРОКСИ-2-ОКСО-3H-1,3-БЕНЗОТИАЗОЛ-7-ИЛ)ЭТИЛАМИДА]ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ПРОЯВЛЯЮЩАЯ АГОНИСТИЧЕСКУЮ АКТИВНОСТЬ В ОТНОШЕНИИ β2-АДРЕНОРЕЦЕПТОРОВ | |
| KR900004804B1 (ko) | 헤테로사이클릭 화합물의 제조방법 | |
| AU2003233244B2 (en) | Therapeutic molecules and methods-1 | |
| SU1400508A3 (ru) | Способ получени производных арилтиазолов | |
| GB2127402A (en) | Pharmaceutically active carbostyril derivatives | |
| US4264613A (en) | Piperidylbenzimidazolinone compounds | |
| SU1470186A3 (ru) | Способ получени гетероциклических соединений | |
| JP3226920B2 (ja) | １，２−ジチオール−３−チオン誘導体に基づく治療組成物 | |
| US4921887A (en) | Thiazole compounds and pharmaceutical composition comprising the same | |
| HU177578B (en) | Process for preparing new 0-/3-amino-2-hydroxy-propyl/-amidoxime derivatives | |
| EP0592664B1 (en) | Derivatives of diphenylthiazole with antiinflammatory activity | |
| JP3081773B2 (ja) | Ｎ−アシルピペラジン誘導体及び抗菌剤、抗潰瘍剤 | |
| FI59086B (fi) | Foerfarande foer framstaellning av 2,5-disubstituerade bensamider | |
| US4517196A (en) | Tricyclic thiazolyloxamic acids and their derivatives, their preparation, and therapeutic agents containing these compounds | |
| KR19980081256A (ko) | 벤즈아미드유도체 및 항궤양제, 항균제 | |
| US4675334A (en) | Tetrazolyl compounds and their use as anti allergic agents | |
| DE2316867C2 (de) | Cephalosporinverbindungen, ihre Salze, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| AU645101B2 (en) | Tetrazole derivative and medicine | |
| PL144860B1 (en) | Method of obtaining novel derivatives of iminothiasolidyne | |
| US5464838A (en) | Aminocarboxylic acid derivatives having antiallergic/antiasthmatic effect and a process for their preparation | |
| US4348403A (en) | 2-Amino-4-(4-benzyloxyphenyl)thiazoles, and their use in hyperlipemia | |
| JPS61260018A (ja) | 抗アレルギ−剤 | |
| US4600721A (en) | Pharmaceutical preparation | |
| SU751007A1 (ru) | 2- @ N-[4-(3,3-Диметилтриазено)-бензолсульфонил]-амидо @ -4,6-диметилпиримидин, про вл ющий противовоспалительное действие |